|

Mid-afternoon market update: Dow tumbles over 200 points, BELLUS Health shares spike higher

Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping 0.58% to 4,684.47.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 50,801,450 cases with around 817,950 deaths. India confirmed a total of at least 34,697,860 cases and 475,630 deaths, while Brazil reported over 22,189,860 COVID-19 cases with 616,940 deaths. In total, there were at least 270,510,600 cases of COVID-19 worldwide with more than 5,324,320 deaths.

Leading and Lagging Sectors

Real estate shares climbed 1.4% on Monday. Meanwhile, top gainers in the sector included Condor Hospitality Trust, Inc. CDOR +8.17% (Get Free Alerts for CDOR), up 8% and Nam Tai Property Inc. NTP +7.13% (Get Free Alerts for NTP) up 6%.

In trading on Monday, energy shares fell 2.5%.

Top Headline

Pfizer Inc PFE +4.62% agreed to acquire Arena Pharmaceuticals Inc ARNA +80.38%, a clinical-stage company developing therapies to treat several immuno-inflammatory diseases.

Under the agreement terms, Pfizer will acquire Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.

Equities Trading UP

Arena Pharmaceuticals, Inc. ARNA +80.38% shares shot up 80% to $89.80. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.

Shares of BELLUS Health Inc. BLU +48.21% got a boost, shooting 52% to $8.49 after the company announced topline data from its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. The data showed that the 50 mg and 200 mg BID doses of BLU-5937 achieved statistical significance on the primary endpoint with a 34% placebo-adjusted reduction in 24-hour cough frequency observed at day 28. 

Foghorn Therapeutics Inc. FHTX +54.96% shares were also up, gaining 34% to $16.05. Loxo Oncology, an R&D group of Eli Lilly And Co LLY +1.87%, and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn's Gene Traffic Control platform.

Equities Trading DOWN

Nisun International Enterprise Development Group Co., Ltd NISN -60.29% shares tumbled 60% to $4.42 after the company priced its $77 million underwritten public offering of common shares and pre-funded warrants to purchase common shares.

Shares of IGM Biosciences, Inc. IGMS -41.31% were down 46% to $26.88 after reporting Phase 1 trial data in advanced B-Cell malignancies. RBC Capital downgraded IGM Biosciences to Sector Perform from Outperform with a price target of $51, down from $90.

Blonder Tongue Laboratories, Inc. BDR -30.8% was down, falling 31% to $0.60 after the NYSE American said it will commence delisting proceedings against Blonder Tongue Laboratories.

Commodities

In commodity news, oil traded down 0.1% to $71.64, while gold traded up 0.2% to $1,789.10.

Silver traded up 0.6% Monday to $22.325 while copper rose 0.1% to $4.2870.

Euro zone

European shares closed lower today. The eurozone’s STOXX 600 slipped 0.43%, the Spanish Ibex Index fell 0.45% and the German DAX 30 slipped 0.01%. Meanwhile, the London’s FTSE 100 fell 0.83%, French CAC 40 fell 0.70% and Italy’s FTSE MIB fell 0.64%.

Wholesale prices in Germany surged 16.6% year-over-year in November following a 15.2% increase a month ago.

Economics

There were no major US economic releases Monday.

Author

Benzinga Team

Benzinga's news desk is a dynamic and innovative team that provides real-time, actionable articles that help readers navigate the market.

More from Benzinga Team
Share:

Editor's Picks

GBP/USD loses momentum, flirts with 1.3200

GBP/USD is struggling to maintain its positive bias on Thursday, retreating toward the 1.3200 region in response to the pick in the buying interest around the Greenback. That said, Cable remains under scrutiny as cautious market sentiment keeps investors focused on the US-Iran conflict and political effervescence in the UK.

EUR/USD trims gains, challenges 1.1400

EUR/USD now gives away part of its earlier advance, receding toward the 1.1400 contention zone on Thursday. Meanwhile, the pair’s recovery comes amid extra losses in the US Dollar, at the time when while investors continue to monitor developments in the Middle East and sentiment surrounding global technology stocks.

Gold remains bid and close to $4,100

Gold accelerates its recovery and approaches the key $4,000 mark per troy ounce at the end of the week, adding to Thursday’s advance. However, expectations for a hawkish Fed remain steady and keep the yellow metal’s potential upside contained.

Crypto Today: Bitcoin at $60,000, Ethereum at $1,500, and XRP at $1 face a make-or-break test

Bitcoin (BTC), Ethereum (ETH), and Ripple (XRP) are trading in the red on Friday after three consecutive days of losses, testing their respective make-or-break support levels.

Week ahead – NFP report to challenge Dollar strength and the hawkish Fed

Dollar strength dominates markets, as the hawkish Fed overshadows geopolitics and lower oil prices. NFP week could drive September Fed hike expectations and boost market volatility. The euro lacks fresh bullish catalysts, all eyes on the preliminary inflation report and the ECB Forum.

Regime change: Inside Kevin Warsh's first move to make the Fed unreadable on purpose

The rate did not move. That was the least interesting thing about Kevin Warsh's first meeting in charge of the Fed. The FOMC held its benchmark at 3.50%-3.75% for the fourth straight meeting, exactly as priced, and then the new chair used his first press conference to dismantle the machinery the market has leaned on for a decade.